Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference
May 06 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will present at the virtual BofA Securities 2020 Health
Care Conference. Mark Iwicki, Chairman, President and Chief
Executive Officer of Kala Pharmaceuticals, is scheduled to present
a corporate overview on Wednesday, May 13th, 2020 at 4:20 p.m.
ET.
To access a live webcast and subsequent archived recording of
the presentation, please visit the “Investors & Media” section
on the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc. Kala is a
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye.
Kala has applied its AMPPLIFYTM mucus penetrating particle Drug
Delivery Technology to a corticosteroid, loteprednol etabonate
(LE), designed for ocular applications, resulting in the January
2019 launch of INVELTYS® (loteprednol etabonate ophthalmic
suspension) 1% and its investigational product candidate, EYSUVISTM
(loteprednol etabonate ophthalmic suspension) 0.25%, which is being
studied for the short-term treatment of the signs and symptoms of
dry eye disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200506005011/en/
Investor Contact: Hannah Deresiewicz
hannah.deresiewicz@sternir.com 212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2024 to Jul 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jul 2023 to Jul 2024